TABLE 3

Summary of endpoints after prenatal SSRI exposure in animals

DrugSpeciesDose AdministrationExposureMaternal Serum Monitored for Drug Conc.5-HTDABehaviorCardioHealthEndpointReference
mg/kg
FLX, FVAMouse0–4.2IPG8–G18Placental transfer++++P20, P90Noorlander et al., 2008
ESC, FLX, PRX, SRT, VENRat3–80OMG12–G21Yes+øøG21–P7, P70–P100Capello et al., 2011
FLXRat10OMG14–P7No+++P30–P120Forcelli and Heinrichs, 2008
CITRat0–20SCG11–P21No++P22–P25Simpson et al., 2011
FLXRat2.5OGG6–G21No+P25Montero et al., 1990
FLXRat10SCG13–G20No+P26, P70Cabrera-Vera et al., 1997
FLXRat10SCG13–G20No+P26Cabrera-Vera and Battaglia 1998
ZIMRat5SCG10–G20Noø+, øP20–P90Grimm and Frieder, 1987
FLXRat12.5OGG8–G20NoøøøP20Stewart et al., 1998
FLXRat8, 12DWG6–G20No++P18–P56Bairy et al., 2007
FLXMouse5, 10SCG13–G20No++P1–P120Cagiano et al., 2008
FLXGuinea pig7OMG1–G54No+øP63Vartazarmian et al., 2005
FLXMouse7.5OGG0–P21No+øP40, P70Lisboa et al., 2007
FLXMouse7.5OGG0–P20No+P90Gouvêa et al. 2008
FLXRat10IPG13–G21No+P56Singh et al., 1998
FLXSheep0.099IVG120–G128Yes+G128Morrison et al., 2001
FLXMouse7.5OGG0–P21No+, ø+P40Favaro et al., 2008
PRXMouse30ChowG14–G16.5Yes+, øP13–P90Coleman et al., 1999
FLXSheep0.099IVG120–-G128YesøøG128Morrison et al., 2005
PRXMouse30ChowG14–P0NoøP34–P105Christensen et al., 2000
FLXRat10OGG11–G21No++G21–P3Fornaro et al., 2007
FLX, VENRat8–80OGG15–G20No+P1da-Silva et al.1999
FLXSheep0.099IVG120–G128Yes+G128Morrison et al., 2004
FLXMouse10DWG0–G21No+G14, G21Bauer et al., 2010
FLXRat10IPG0–BFNo+P3–P30Periera et al., 2007
PRXRat10DWG14–G21No+P0Van den Hove et al., 2008
FLXRat10IPG9–G11NoøG21Swerts et al., 2010
FLXRat/rabbit0–15OGG6–G15NoøG20/G28Byrd and Markham, 1994

  • +, Positive association; ø, null association; BF, breast feeding; CIT, citalopram; DW, drinking water; ESC, escitalopram; FLX, fluoxetine; FVA, fluvoxamine; G, gestation day; IV, intravenous; IP, intraperitoneal; OG, oral gavage; OM, subcutaneous osmotic minipump; P, postnatal day; SC, subcutaneous; SRT, sertraline; VEN, venlafaxine; ZIM, zimelidine.